Rani Therapeutics Cash and Securities Total $49.7M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 26 2026
0mins
Cash, cash equivalents and marketable securities as of December 31, 2025 totaled $49.7M, compared to $27.6M for the year ended December 31, 2024. Rani expects its cash, cash equivalents and marketable securities, including an expected technology transfer milestone payment pursuant to the Chugai agreement, to be sufficient to fund its operations into the fourth quarter of 2027. "We entered 2026 at an important inflection point, highlighted by the initiation of our Phase 1 study of RT-114, our first orally administered GLP-1/GLP-2 dual agonist delivered via the RaniPill capsule," said Talat Imran, CEO of Rani Therapeutics. "Throughout 2025, we generated a robust body of preclinical evidence for RT-114 and our oral semaglutide, demonstrating the potential of the RaniPill platform to enable oral delivery of complex incretin-based therapies. We also strengthened our balance sheet through an oversubscribed private placement led by a premier syndicate of investors and entered into a collaboration and license agreement with Chugai. With the initiation of our Phase 1 trial of RT-114 in December 2025, we are well positioned to advance our first oral GLP-1/GLP-2 dual agonist into clinical development and continue unlocking the potential of the RaniPill(R) platform across high-value therapeutic areas. We look forward to building on the momentum of 2025 as we execute on our clinical, strategic, and partnership objectives in the year ahead."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RANI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RANI
Wall Street analysts forecast RANI stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.896
Low
9.00
Averages
10.00
High
11.00
Current: 0.896
Low
9.00
Averages
10.00
High
11.00
About RANI
Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. The Company has developed the RaniPill capsule, which is a proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. The RaniPill capsule is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. It has two configurations of the platform: the RaniPill GO and the RaniPill HC. The RaniPill GO is designed to deliver up to a 3 mg dose of drug in microtablet form with high bioavailability. It is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC. Its product candidate pipeline includes obesity programs (RT-114 and RT-116), immunology programs (RT-105 and RT-111) and endocrinology programs (RT-102 and RT-110).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Rani Therapeutics Announces Direct Offering of Shares and Warrants
- Financing Agreement: Rani Therapeutics announced a securities purchase agreement with H.C. Wainwright & Co. to issue 12.48 million Class A shares at $1.07 each, expecting to raise approximately $20 million in gross proceeds, enhancing liquidity to support future R&D initiatives.
- Pre-Funded Warrants: The offering includes 6.21 million pre-funded warrants with an exercise price of $0.0001 each, lowering the entry barrier for investors and potentially attracting more capital to support the company's strategic growth.
- Transaction Timeline: The deal is expected to close on or around May 27, 2026, ensuring timely access to funds for operational and project advancement, reflecting the company's keen market timing.
- Financial Performance Overview: Rani Therapeutics' recent earnings report indicated a GAAP EPS of -$0.04 and revenue of $1.7 million, beating expectations by $1.2 million, showcasing the company's growth potential and market confidence amid the current financing backdrop.
See More
Rani Therapeutics Reports Q1 Earnings Highlights
- Earnings Performance: Rani Therapeutics reported a Q1 GAAP EPS of -$0.04, aligning with market expectations, indicating financial stability amidst operational challenges.
- Surge in Contract Revenue: The company achieved contract revenue of $1.7 million, a remarkable 900% year-over-year increase, exceeding expectations by $1.2 million, reflecting significant progress in market demand and business expansion.
- Cash Reserves Status: As of March 31, 2026, Rani's cash, cash equivalents, and marketable securities totaled $43.4 million, down from $49.7 million as of December 31, 2025, highlighting a cautious approach to fund utilization.
- Funding Outlook: Rani expects its cash reserves to be sufficient to fund operations into Q4 2027, particularly with an anticipated technology transfer milestone payment from its collaboration with Chugai, demonstrating confidence in future operational sustainability.
See More
Rani Therapeutics CFO Departure and Leadership Changes Announced
- Executive Changes: Rani Therapeutics announced the departure of CFO Svai Sanford after a successor is appointed, indicating significant leadership adjustments to address future challenges and opportunities.
- Transition Support: Sanford will remain during the transition period to ensure a smooth handover, a move aimed at maintaining operational stability and minimizing potential management risks.
- Performance Highlights: In its first quarter report, Rani achieved contract revenue of $1.7 million, a staggering 900% year-over-year increase, exceeding market expectations by $1.2 million, showcasing the company's strong business expansion momentum.
- Market Reaction: Despite the robust contract revenue performance, Rani's stock fell 2% in after-hours trading, reflecting investor caution regarding the company's overall financial performance, particularly with a GAAP EPS of -$0.04, which was in line with expectations.
See More
Rani Therapeutics Q4 Earnings Report Analysis
- Earnings Performance: Rani Therapeutics reported a Q4 GAAP EPS of -$0.07, aligning with market expectations, but its revenue of $1.46 million, despite a 41.7% year-over-year increase, fell short by $3.54 million, indicating challenges in revenue growth.
- Cash Position: As of December 31, 2025, Rani's cash, cash equivalents, and marketable securities totaled $49.7 million, a significant increase from $27.6 million in 2024, reflecting improvements in the company's financial management.
- Funding Adequacy: Rani expects its cash and cash equivalents to be sufficient to fund operations into Q4 2027, including an anticipated technology transfer milestone payment from the Chugai agreement, demonstrating confidence in future cash flow.
- Market Outlook: Despite missing revenue expectations, Rani is actively pursuing technology transfers and partnerships to enhance its market competitiveness and drive future growth, reflecting ongoing strategic efforts.
See More
Multiple Companies Set to Report Earnings
- Argan, Inc. Earnings Forecast: Argan, Inc. is expected to report earnings per share of $1.99 for the quarter ending January 31, 2026, reflecting a 10.36% decrease compared to the same quarter last year, indicating volatility in its profitability despite beating expectations in two other quarters over the past year.
- Oxford Industries, Inc. Performance Outlook: Oxford Industries anticipates earnings per share of only $0.05, representing a significant 96.35% decline year-over-year, highlighting severe challenges in the competitive textile industry, although the company has exceeded expectations three times in the past year.
- Veritone, Inc. Earnings Projection: Veritone is forecasting earnings per share of -$0.10, which is a 60.00% increase from the same quarter last year, yet it failed to meet consensus expectations in the first quarter of 2025, reflecting instability in its earnings potential.
- Braskem S.A. Financial Condition: Braskem is projected to report earnings per share of -$0.98, a staggering 151.28% decrease compared to the same quarter last year, indicating ongoing difficulties in the chemical sector, and it missed consensus expectations in the fourth quarter of 2024, underscoring persistent pressure on its profitability.
See More
Rani Therapeutics Appoints New Head of Strategy, Shares Surge
- Leadership Change: Rani Therapeutics appointed Jesper Hoiland as Head of Strategy, resulting in a pre-market share price surge of over 15%, indicating strong market confidence in the company's strategic direction and potential advancements in biopharmaceuticals.
- Pipeline Progress: Rani's investigational pipeline includes RT-114 for obesity, currently in Phase 1 trials in collaboration with ProGen, while the company's net loss for Q3 2025 narrowed to $7.9 million from $12.7 million, suggesting improved financial health.
- Strong Financial Position: As of September 30, 2025, Rani reported cash and cash equivalents totaling $4.1 million, expected to fund operations into 2028, demonstrating robust financial management and sustainability.
- Market Recovery: Rani's stock has traded between $0.38 and $3.87 over the past year, closing at $1.14, with a pre-market increase of 15.79% to $1.32, reflecting investor optimism regarding the company's growth potential.
See More
Rani Therapeutics Announces Direct Offering of Shares and Warrants
- Financing Agreement: Rani Therapeutics announced a securities purchase agreement with H.C. Wainwright & Co. to issue 12.48 million Class A shares at $1.07 each, expecting to raise approximately $20 million in gross proceeds, enhancing liquidity to support future R&D initiatives.
- Pre-Funded Warrants: The offering includes 6.21 million pre-funded warrants with an exercise price of $0.0001 each, lowering the entry barrier for investors and potentially attracting more capital to support the company's strategic growth.
- Transaction Timeline: The deal is expected to close on or around May 27, 2026, ensuring timely access to funds for operational and project advancement, reflecting the company's keen market timing.
- Financial Performance Overview: Rani Therapeutics' recent earnings report indicated a GAAP EPS of -$0.04 and revenue of $1.7 million, beating expectations by $1.2 million, showcasing the company's growth potential and market confidence amid the current financing backdrop.
See More
Rani Therapeutics Reports Q1 Earnings Highlights
- Earnings Performance: Rani Therapeutics reported a Q1 GAAP EPS of -$0.04, aligning with market expectations, indicating financial stability amidst operational challenges.
- Surge in Contract Revenue: The company achieved contract revenue of $1.7 million, a remarkable 900% year-over-year increase, exceeding expectations by $1.2 million, reflecting significant progress in market demand and business expansion.
- Cash Reserves Status: As of March 31, 2026, Rani's cash, cash equivalents, and marketable securities totaled $43.4 million, down from $49.7 million as of December 31, 2025, highlighting a cautious approach to fund utilization.
- Funding Outlook: Rani expects its cash reserves to be sufficient to fund operations into Q4 2027, particularly with an anticipated technology transfer milestone payment from its collaboration with Chugai, demonstrating confidence in future operational sustainability.
See More
Rani Therapeutics CFO Departure and Leadership Changes Announced
- Executive Changes: Rani Therapeutics announced the departure of CFO Svai Sanford after a successor is appointed, indicating significant leadership adjustments to address future challenges and opportunities.
- Transition Support: Sanford will remain during the transition period to ensure a smooth handover, a move aimed at maintaining operational stability and minimizing potential management risks.
- Performance Highlights: In its first quarter report, Rani achieved contract revenue of $1.7 million, a staggering 900% year-over-year increase, exceeding market expectations by $1.2 million, showcasing the company's strong business expansion momentum.
- Market Reaction: Despite the robust contract revenue performance, Rani's stock fell 2% in after-hours trading, reflecting investor caution regarding the company's overall financial performance, particularly with a GAAP EPS of -$0.04, which was in line with expectations.
See More
Rani Therapeutics Q4 Earnings Report Analysis
- Earnings Performance: Rani Therapeutics reported a Q4 GAAP EPS of -$0.07, aligning with market expectations, but its revenue of $1.46 million, despite a 41.7% year-over-year increase, fell short by $3.54 million, indicating challenges in revenue growth.
- Cash Position: As of December 31, 2025, Rani's cash, cash equivalents, and marketable securities totaled $49.7 million, a significant increase from $27.6 million in 2024, reflecting improvements in the company's financial management.
- Funding Adequacy: Rani expects its cash and cash equivalents to be sufficient to fund operations into Q4 2027, including an anticipated technology transfer milestone payment from the Chugai agreement, demonstrating confidence in future cash flow.
- Market Outlook: Despite missing revenue expectations, Rani is actively pursuing technology transfers and partnerships to enhance its market competitiveness and drive future growth, reflecting ongoing strategic efforts.
See More
Multiple Companies Set to Report Earnings
- Argan, Inc. Earnings Forecast: Argan, Inc. is expected to report earnings per share of $1.99 for the quarter ending January 31, 2026, reflecting a 10.36% decrease compared to the same quarter last year, indicating volatility in its profitability despite beating expectations in two other quarters over the past year.
- Oxford Industries, Inc. Performance Outlook: Oxford Industries anticipates earnings per share of only $0.05, representing a significant 96.35% decline year-over-year, highlighting severe challenges in the competitive textile industry, although the company has exceeded expectations three times in the past year.
- Veritone, Inc. Earnings Projection: Veritone is forecasting earnings per share of -$0.10, which is a 60.00% increase from the same quarter last year, yet it failed to meet consensus expectations in the first quarter of 2025, reflecting instability in its earnings potential.
- Braskem S.A. Financial Condition: Braskem is projected to report earnings per share of -$0.98, a staggering 151.28% decrease compared to the same quarter last year, indicating ongoing difficulties in the chemical sector, and it missed consensus expectations in the fourth quarter of 2024, underscoring persistent pressure on its profitability.
See More
Rani Therapeutics Appoints New Head of Strategy, Shares Surge
- Leadership Change: Rani Therapeutics appointed Jesper Hoiland as Head of Strategy, resulting in a pre-market share price surge of over 15%, indicating strong market confidence in the company's strategic direction and potential advancements in biopharmaceuticals.
- Pipeline Progress: Rani's investigational pipeline includes RT-114 for obesity, currently in Phase 1 trials in collaboration with ProGen, while the company's net loss for Q3 2025 narrowed to $7.9 million from $12.7 million, suggesting improved financial health.
- Strong Financial Position: As of September 30, 2025, Rani reported cash and cash equivalents totaling $4.1 million, expected to fund operations into 2028, demonstrating robust financial management and sustainability.
- Market Recovery: Rani's stock has traded between $0.38 and $3.87 over the past year, closing at $1.14, with a pre-market increase of 15.79% to $1.32, reflecting investor optimism regarding the company's growth potential.
See More
